Association Between Dose and Plasma Concentration of Bisoprolol in Patients with Heart Failure (CVI ARO 6).


Journal

International heart journal
ISSN: 1349-3299
Titre abrégé: Int Heart J
Pays: Japan
ID NLM: 101244240

Informations de publication

Date de publication:
30 Jul 2020
Historique:
pubmed: 21 7 2020
medline: 13 8 2020
entrez: 21 7 2020
Statut: ppublish

Résumé

Although bisoprolol is used widely to treat patients with heart failure (HF), little information is available regarding the association between the dose of bisoprolol administered and the bisoprolol plasma concentration (Bis-PC) in real-world clinical practice.This was a single-center, observational study in 114 patients with HF receiving once-daily bisoprolol. After determination of trough Bis-PC, the relationship between the dose of bisoprolol and Bis-PC was analyzed. In a multiple linear regression model, the dose of bisoprolol and estimated creatinine clearance (reciprocal number) were identified as independent predictors. HF severity and hepatic function were not associated with Bis-PC.Bis-PC was increased by renal dysfunction, which explained most of the discrepancy between the dose of bisoprolol administered and Bis-PC.

Identifiants

pubmed: 32684605
doi: 10.1536/ihj.20-052
doi:

Substances chimiques

Adrenergic beta-1 Receptor Antagonists 0
Bisoprolol Y41JS2NL6U

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

748-754

Auteurs

Takuto Arita (T)

Department of Cardiovascular Medicine, The Cardiovascular Institute.

Shinya Suzuki (S)

Department of Cardiovascular Medicine, The Cardiovascular Institute.

Yuko Kato (Y)

Department of Cardiovascular Medicine, The Cardiovascular Institute.

Hiroto Kano (H)

Department of Cardiovascular Medicine, The Cardiovascular Institute.

Junji Yajima (J)

Department of Cardiovascular Medicine, The Cardiovascular Institute.

Shunsuke Matsuno (S)

Department of Cardiovascular Medicine, The Cardiovascular Institute.

Takayuki Otsuka (T)

Department of Cardiovascular Medicine, The Cardiovascular Institute.

Hiroaki Semba (H)

Department of Cardiovascular Medicine, The Cardiovascular Institute.

Tokuhisa Uejima (T)

Department of Cardiovascular Medicine, The Cardiovascular Institute.

Yuji Oikawa (Y)

Department of Cardiovascular Medicine, The Cardiovascular Institute.

Kazuyuki Nagashima (K)

Department of Cardiovascular Medicine, The Cardiovascular Institute.

Naoharu Yagi (N)

Department of Cardiovascular Medicine, The Cardiovascular Institute.

Koichi Sagara (K)

Department of Cardiovascular Medicine, The Cardiovascular Institute.

Gen Tanabe (G)

Department of Cardiovascular Medicine, The Cardiovascular Institute.

Takeshi Yamashita (T)

Department of Cardiovascular Medicine, The Cardiovascular Institute.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH